KALARIS THERAPEUTICS, INC. Restructuring Costs
KALARIS THERAPEUTICS, INC. (KLRS) reported Restructuring Costs of $10.19 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2025-03-07
- KALARIS THERAPEUTICS, INC. restructuring costs for the quarter ending 2024-12-31 was $126.00K.
- KALARIS THERAPEUTICS, INC. restructuring costs for the quarter ending 2024-09-30 was $83.00K.
- KALARIS THERAPEUTICS, INC. restructuring costs for the quarter ending 2024-06-30 was $512.00K.
- KALARIS THERAPEUTICS, INC. restructuring costs for the quarter ending 2024-03-31 was $9.46M.
- KALARIS THERAPEUTICS, INC. restructuring costs for fiscal 2024 was $10.19M.
- KALARIS THERAPEUTICS, INC. restructuring costs for fiscal 2023 was $0.00.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $126.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $209.00K derived: sum of 2 quarters · filed 2025-03-07 | $721.00K derived: sum of 3 quarters · filed 2025-03-07 | $10.19M 10-K · filed 2025-03-07 |
| 2024-09-30 | $83.00K 10-Q · filed 2024-11-12 | $595.00K derived: sum of 2 quarters · filed 2024-11-12 | $10.06M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $512.00K 10-Q · filed 2024-08-09 | $9.98M 10-Q · filed 2024-08-09 | ||
| 2024-03-31 | $9.46M 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |